<DOC>
	<DOCNO>NCT00788528</DOCNO>
	<brief_summary>The purpose open-label extension study evaluate safety efficacy velneperit ( S-2367 ) obese subject .</brief_summary>
	<brief_title>Open-Label Extension ( OLE ) Study Safety Efficacy Velneperit ( S-2367 ) Obese Subjects</brief_title>
	<detailed_description />
	<criteria>Must complete randomized treatment visit reduce calorie diet ( RCD , Shionogi protocol 0701A2823 ) low calorie diet ( LCD , Shionogi protocol 0702A2824 ) study include Visit 13 Medically stable throughout controlled clinical trial treatment period otherwise good health , clinically significant finding medical history , physical examination , 12lead ECG , vital sign Clinical laboratory evaluation ( include clinical chemistry [ fast least 8 hour ] , complete blood count , urinalysis , include creatine phosphokinase , amylase , lipase , lipid profile , insulin Homeostatic Model Assessment Insulin Sensitivity Index within reference range test laboratory , unless deem clinically significant Investigator Males sterile agree continue use approve method contraception . Some approve method contraception male include surgically sterile ( least 3 month prior Visit 13/20 ) female sexual partner ; postmenopausal ( least 1 year since last menstrual cycle ) female sexual partner ; female sexual partner us ( least previous 3 month prior Visit 13/20 study ) oral , implantable , transdermal , injectable contraceptive ; use follow doublebarrier method : male condom spermicide Females nonpregnant , nonlactating , either postmenopausal least 1 year since last menstrual period , surgically sterile least 3 month prior Visit 13/20 , agree use approve method contraception . Some approve method contraception female include sterile ( least 3 month prior Visit 13/20 ) male sexual partner ; use oral , implantable , transdermal , injectable contraceptive ; use one follow doublebarrier method : intrauterine device spermicide , diaphragm spermicide , cervical cap spermicide , female condom spermicide , male condom spermicide male sexual partner Able understand willing sign inform consent form comply study procedure History clinical manifestation significant metabolic , hepatic , immunological ( e.g. , human immunodeficiency virus/acquired immunodeficiency syndrome ) , renal , hematological , pulmonary , cardiovascular , gastrointestinal ( GI ) , urological , neurological psychiatric disorder Current abnormal ECG , , Investigator 's opinion , clinically significant Current evidence psychological disorder , stable control anxiety depression include , limited schizophrenia . Treatment antidepressant anxiolytic drug ( ) permit medication preclude / exclude protocol potential effect body weight expected change remainder clinical protocol A score 10 either Anxiety Depression portion Hospital Anxiety Depression Scale ( HADS ) Visit 13/20 . Subjects whose HADS score Visit 13/20 exceed 10 either Anxiety Depression portion HADS allow study examine determine symptom anxiety and/or depression severity incompatible treatment velneperit . Permission must also obtain Sponsor Sponsor 's designated medical representative subject score 10 HADS subscores Current obesity endocrine origin Current Type 1 Type 2 diabetes mellitus Current clinically significant hypertension , define blood pressure &gt; 160/90 mmHg either systolic diastolic value either untreated treat state Current plan clinically significant GI surgery . Note : Appendectomy cholecystectomy allow Current plan gastric bypass surgery , stomach band surgery , surgical procedure ( ) attempt promote/aid weight loss . Note : Liposuction allow do 3 month prior Study Visit 20 Current polycystic ovarian syndrome Current plan participation weight loss program outside program describe openlabel extension ( OLE ) study Current alcoholism drug addiction/substance abuse . Note : Alcohol use study allow provide `` routine '' daily consumption less equal 2 units/day ( 1 unit equivalent 12 oz . beer , 5 oz . wine , 1.5 oz . 80proof distilled spirit [ equivalent ] ) except alcohol consumption allow within 48 hour prior blood collection analysis lipid profile Current use tobaccocontaining nicotinecontaining product ( include cigarette , pipe , cigar , chew , nicotine patch , nicotine gum Current plan participation investigational study drug trial receipt investigational study drug occur Current plan participation weight loss medication/product study receipt weight loss medication/product occur Current plan use prescription nonprescription overthecounter ( OTC ) medication/product herbal/phytotherapeutic/plantderived medications/products intend induce weight loss , appetite suppression , weight control treat obesity , include , limited , phentermine , sibutramine , orlistat , ephedra , rimonabant anorexogenics and/or stimulant , well topiramate , etc . Note : Use medications/products weight control , appetite suppression , treatment obesity prohibit course OLE study Current plan use chronic medications/products know cause weight gain entire OLE study . The list include limited amitriptyline ( ELAVIL ) , paroxetine ( PAXIL ) , setraline ( ZOLOFT ) , mirtazepine ( REMERON ) . Additional clarification provide concomitant medication section Appendix B update clarification section . Investigators discuss Sponsor 's Medical Monitor concomitant medication uncertain Current plan use prescription nonprescription OTC medications/product , unless deem acceptable Investigator . Some example allow medication stable use ( RCD LCD Study ) : hormone replacement therapy ( e.g. , postmenopausal woman ) ; antihypertensive agent ( e.g. , hypertensive subject ) ; statin ( e.g. , hyperlipidemia ) ; thyroid replacement therapy ( e.g. , hypothyroid subject provide thyroid replacement therapy stable RCD LCD study clinically significant change thyroid stimulate hormone and/or free thyroxine occur [ ] study ) ; oral , implantable , transdermal , injectable contraceptive ( ) , etc . Anticholinergics ( use acutely ) , centrally act antihistamine , antiinflammatories also allow . Continued , stable , moderate use ( RCD LCD study ) vitamins mineral allow additional use multivitaminmineral supplement ( nonherbal ) may allow Investigator ( designee ) part study diet program Planned donation blood blood product entire OLE study Current poor peripheral venous access would preclude blood collection Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Obesity</keyword>
</DOC>